CPTR title slide. Daniela M Cirillo San Raffaele Scientific Institute NDWG-Cochair
|
|
- Myles Jennings
- 6 years ago
- Views:
Transcription
1 CPTR title slide Daniela M Cirillo San Raffaele Scientific Institute NDWG-Cochair
2 Outline The global threat of Drug Resistant TB Actions to control MDR-TB Barriers to implement universal screening for DR Potential and limitation of current molecular tools The need for a centralized database
3 Outline The global threat of Drug Resistant TB Actions to control MDR-TB Barriers to implement universal screening for DR Potential and limitation of current molecular tools The need for a centralized database
4 Drug Resistance: a threat for TB control 9.6 MILLION estimated TB cases Facts: 9.6 million TB cases 1.5 million TB deaths
5 Drug Resistance: a threat for TB control 9.6 MILLION estimated TB cases Facts: 9.6 million TB cases 1.5 million TB deaths 3.6 million undiagnosed Up to 30% of cases diagnosed never get treated 123,000 MDR-TB cases diagnosed 6 MILLION new cases diagnosed Facts: with MDR Only 12 % new + 58% prev. treated are diagnosed
6 MDR is transmitted more than acquired State of the art mechanistic mathematical modeling approach show that the VAST majority of MDRTB cases in high burden settings are due to TRANSMISSION rather than ACQUISITION during therapy Consequences: Addressing the management of sensitive TB doesn t control MDR Targeted screening of individuals with MDR is highly insufficient Decentralization of DRTB diagnosis and testing with patients/clinicians friendly diagnostics and lesser toxic drugs
7 Outline The global threat of Drug Resistant TB Actions to control MDR-TB Barriers to implement universal screening for DR Potential and limitation of current molecular tools The need for a centralized database
8 Actions Universal screening for Drug Resistance Use drugs according to the drug resistance pattern Use only effective drugs in shorter regimens
9 Outline The global threat of Drug Resistant TB Actions to control MDR-TB Barriers to implement universal screening for DR Potential and limitation of current molecular tools The need for a centralized database
10 Fundamental knowledge is still missing for many drugs: break points and ECOFF Critical concentration (or cut-off) It refers to a testing method It is the lowest drug concentration that inhibit growth of at least 95% of strains never exposed to the drug tested and that simultaneously does not suppress resistant strains ECOFF MIC value identifying the upper limit of the wild type population Lineage-related variability
11 DST Critical Concentration WHO, 2008 WHO, 2012
12 Banu S et al, JCM 2014 Concordance among different tests Complete concordance among phenotypic tests: 82% 77% 50% 51%
13 Phenotypic methods : challenges and limitations Phenotypic methods: Require a positive culture Require appropriate infrastructure Require technical capacity Require fast and temperature controlled referral of samples containing class 3 microorganisms SC LC time to DST time to DST Standardization issues: Media Critical concentration Mechanism of action non compatible with in vitro testing Cost Time to results Quality of results day >60 Average contamination rate in low resources settings: 15-35% liquid culture 1-15 solid cultures
14 Outline The global threat of Drug Resistant TB Actions to control MDR-TB Barriers to implement universal screening for DR Potential and limitation of current molecular tools The need for a centralized database
15 Potential of molecular diagnostics User-friendly molecular diagnostics will increase accessibility to proper diagnosis of DR Reducing inequality due to poor accessibility to DST Reducing cost and suffering due to side effects Increase accessibility to new drugs in a protected manner Decreasing direct transmission in community by achieving early sterilization Decreasing the generation of additional resistance due to improper treatment
16 Xpert MTB rif roll out: a successful story showing potential and limitations of molecular Current screening based on molecular detection of mutations in rpob hot spot as proxy for rifampicin resistance
17 Coverage of identified SNPs by Xpert MTB/RIF Region # of SNPs Xpert MTB/RIF RRDR /366 (99.2%) Outside RRDR within rpob 24 0/24 (0.0%) Non-resistance conferring mutations* 16 5/16 (31.3%) * Non-resistance conferring mutations in rpob gene are silent mutations because we do not have mutations clearly not associated with R. rpob RRDR spans from cod. 505 to cod. 537: Xpert MTB/RIF: F514F, L533L, T525T, R529R, L521L Courtesy of Paolo Miotto
18 Theoretical accuracy of molecular tests for RR detection in clinical isolates All strains with confirmed mutations* # of strains Genotype MTBDRplus NIPRO Sensitivity (95% CIs) ( ) Specificity (95% CIs) ( ) Sensitivity (95% CIs) ( ) Specificity (95% CIs) ( ) All strains with confirmed mutations* # of strains Xpert MTB/RIF Sensitivity (95% CIs) ( ) Specificity (95% CIs) ( ) * Excludes strains for which there is uncertainty on how to classify the mutation (minimal confidence and indeterminate) but includes all strains with mutations within or outside RRDR and non-resistance conferring genetic variants Courtesy of Paolo Miotto
19 Limitations of current genotypic methods Commercially available for few drugs with variable diagnostic accuracy Targeting the most relevant genes (not all) and often only hot spots Difficulties in the interpretations of the results Overall not perceived as fully trustable
20 L430 Q432 D435 S441 H445 S450 L452 Limit of Xpert MTB/RIF: Swaziland WHO recommended first-line Dx test to identify MDR-TB 81 bp hotspot region within rpob ( ) Majority of rifampicin mutations associated with DR 30% of MDR strains carried a I491F mutation Review of 2009 survey (1% prevalence of TB) 491 position not included in Xpert MTB/RIF V65F V176F P206R Y314C H323Y R426H rifampicin resistance-determining region (RRDR) Sanchez-Padilla et al., 2015 NEJM
21 LPAs Tagliani et al JCM 2015
22 WGS Virulence determinants Identification Genotyping All-in-one Drug-resistance Evolution Phylogenesis Population structure
23
24 Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study Timothy M Walker, DrMRCP, Thomas A Kohl, PhD, Shaheed V Omar, MSc, Jessica Hedge, PhD, Carlos Del Ojo Elias, MSc, Phelim Bradley, MPhil, Zamin Iqbal, DPhil, Silke Feuerriegel, PhD, Katherine E Niehaus, MS, Daniel J Wilson, DPhil, David A Clifton, DPhil, Georgia Kapatai, PhD, Camilla L C Ip, PhD, Rory Bowden, PhD, Francis A Drobniewski, PhD, Caroline Allix-Béguec, PhD, Cyril Gaudin, PhD, Julian Parkhill, PhD, Roland Diel, PhD, Philip Supply, PhD, Derrick W Crook, FRCPath, E Grace Smith, FRCPath, A Sarah Walker, PhD, Nazir Ismail, FCPath, Stefan Niemann, PhD, Tim E A Peto, FRCP The Lancet Infectious Diseases DOI: /S (15) The Lancet Infectious Diseases DOI: ( /S (15) ) Copyright 2015 Walker et al. Open Access article distributed under the terms of CC-BY Terms and Conditions
25 Outline The global threat of Drug Resistant TB Actions to control MDR-TB Barriers to implement universal screening for DR Potential and limitation of current molecular tools The need for a centralized database
26 Lesson learnt from diagnostic implementations Phenotypic methods are too slow and too demanding to be adopted as routine methods to start patients on appropriate therapy Implementation and maintenance of capacity for DST is more challenging that implementation of molecular diagnostics Liquid DST has limitations and it is highly challenged by the required infrastructure, cost, contamination rate, Performance of Molecular tests depends on strains circulating in a geographical area
27 Existing barriers to develop fully comprehensive molecular assays Lack of or incomplete knowledge associating SNPs to mechanisms of resistance and mic Resistance markers in multiple genes Unclear link between mutations and clinical outcomes Presence of mutations not associated to resistance Poor and inconsistent DST and mic data, unclear CC, Heteroresistance Geographic differences, clone spreading
28 Current hurdles Data sets scattered across a high number of studies Rare mutations under represented Different studies use different methods (liquid/solid, CCs, SNP detection approach...) Few studies correlating SNP to MICs, MICs in broth not always reliable Few studies correlating SNP with clinical outcome Few mutations supported by functional genetics Need to be comprehensive and based on common standards
29 The need for a database for TB Standardized Understand SNP-DST relationships (including MIC and cross-resistance) Understand SNP-clinical outcome relationships Standardize interpretation of SNPs more complex interactions Global Understand frequency of mutations Understand the geographical distribution of mutations Improve statistical power for rare mutations Evaluate the global picture taking into account strains diversity, evolution, compensatory mutations, more complex interactions
30 Multiple databases with global representation ( quality assessed) Standardized to CDISC investigational database Retain original data ownership and decide on level of access Incorporation of statistical and graphing analysis tools Experts driven process : experts includes different areas of expertise and represents different settings
31 Main differences with other existing databases
32 Collaborative efforts to produce high quality data
33
34 Conclusion If the statistical power required to cover the possible variants is met the following could be achieved: accurate genetic resistance prediction for existing and new TB drugs by WGS; superior design of near-to-patient amplification-based molecular drug-resistance tests as alternatives to WGSonly solutions; better, faster and finally individualized treatment of drugresistant TB with positive impact on treatment outcomes and transmission of the disease
35 Thank You! CDC DTBE and NIAID
BENEFITS AND LIMITATIONS OF MOLECULAR TESTING
BENEFITS AND LIMITATIONS OF MOLECULAR TESTING Test performance/ selection in various settings Edward Desmond, Ph.D., D (ABMM) California Dept. of Public Health Problem Pascopella, et al. 2004. Laboratory
More information9th National Conference on the Laboratory Aspects of Tuberculosis
9th National Conference on the Laboratory Aspects of Tuberculosis Expected discrepancies between molecular and growth-based DST: Which technology is giving the right answer? Edward Desmond, CA Dept. of
More informationEvolution of Next Generation Sequencing Technology: Ready for Patient Management?
Evolution of Next Generation Sequencing Technology: Ready for Patient Management? Timothy Rodwell MD, PhD, MPH Senior Scientific Officer at FIND 3 rd December 2015, Union Meeting Cape Town Clinical Utility
More informationMycobacterium tuberculosis and Drug- Resistance Testing
Mycobacterium tuberculosis and Drug- Resistance Testing Dr. med. Peter Keller, FAMH Medical Microbiology Head Molecular Diagnostics pkeller@imm.uzh.ch 08.03.2018 Molecular Diagnostics 2018 Page 1 Mycobacteria
More informationAuthor s response to reviews
Author s response to reviews Title: PLASMID-BASED HIGH-RESOLUTION MELTING ANALYSIS FOR ACCURATE DETECTION OF RPOB MUTATIONS IN MYCOBACTERIUM TUBERCULOSIS ISOLATES FROM MOROCCAN PATIENTS Authors: El Mehdi
More informationUsing WGS data to predict DRTB phenotypes: A CRyPTIC experience. Timothy M Walker
Using WGS data to predict DRTB phenotypes: A CRyPTIC experience Timothy M Walker CRyPTIC Comprehensive Resistance Prediction for Tuberculosis: an international consortium http://www.crypticproject.org
More informationFaramarz Valafar.
Faramarz Valafar faramarz@sciences.sdsu.edu http://informatics.sdsu.edu/ Biomedical Informatics Research Center (BMIRC) Office: GMCS 625 San Diego State University Molecular Diagnostics for Drug Resistant
More informationWGS-based susceptibility testing for TB: from research to service delivery Update from National Mycobacterial Reference Service
WGS-based susceptibility testing for TB: from research to service delivery Update from National Mycobacterial Reference Service Grace Smith. National Mycobacterial Reference Service. Public Health England
More informationLaboratory Methods: Tuberculosis Diagnosis
Laboratory Methods: Tuberculosis Diagnosis Grace Lin Research Scientist MDL, CA Dept of Public Health Grace.lin@cdph.ca.gov Curry International TB Center 10-19-17 Topics Diagnostic testing Smear and Culture
More informationRapid molecular diagnosis of TB and drug-resistant TB
Rapid molecular diagnosis of TB and drug-resistant TB 2 nd European Advanced Course in Clinical Tuberculosis Amsterdam 2014 J. Domínguez Institut d Investigació Germans Trias i Pujol Universitat Autònoma
More informationAssessing quality-assured diagnoses made by TB laboratories
Assessing quality-assured diagnoses made by TB laboratories Quality-assured TB laboratory Objectives: at the end of the assessment reviewers should comment on the laboratory network and its structure;
More informationPlanning a future with expanded molecular DST
Planning a future with expanded molecular DST Find Symposium Daniela M. Cirillo Emerging Bacterial Pathogens Unit (EBPU), San Raffaele Scientific Institute, Milan, Italy Outline Where we come from Needs
More informationWhat Are We Trying to Say Here? Standardizing Next Generation Sequencing Reports for Tuberculosis
Jeffrey Tornheim, MD MPH Clinical Fellow in Infectious Diseases Johns Hopkins University School of Medicine tornheim@jhu.edu What Are We Trying to Say Here? Standardizing Next Generation Sequencing Reports
More informationUsing new TB diagnostic tools: What is ( and is not) ready for prime time???
Using new TB diagnostic tools: What is ( and is not) ready for prime time??? Eiman Mokaddas MD, FRCPath Professor of Clinical Microbiology Faculty of Medicine Kuwait University Footer Text 8/6/2015 1 Outline
More informationRequest for Applications: PHL Reference Center for Mycobacterium tuberculosis complex Drug Susceptibility Testing
Request for Applications: PHL Reference Center for Mycobacterium tuberculosis complex Drug Susceptibility Testing Application Due Date: October 13, 2014 Submit to: Kelly Wroblewski, Director of Infectious
More informationNational and International Trends in Tuberculosis. Edward Desmond Microbial Diseases Laboratory California Dept. of Public Health
National and International Trends in Tuberculosis Edward Desmond Microbial Diseases Laboratory California Dept. of Public Health Trend 1: The number of TB cases is decreasing In the USA (significantly),
More informationWhy is the laboratory so confusing? Why don t all laboratories do it the same way?
Journey to the Center of the MTB Complex (Making Sense of Laboratory Test Results in TB Management) Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory/Division of Tuberculosis Elimination
More informationRapid Diagnosis of Tuberculosis
Rapid Diagnosis of Tuberculosis Ed DESMOND Richmond, US I. Rapid Diagnosis Methods I would like to discuss rapid diagnosis methods of tuberculosis. The traditional method is acid fast microscopy. However,
More informationProgrammatic Implementation of NGS for TB & Future Plans for the ReSeqTB Knowledgebase
Programmatic Implementation of NGS for TB & Future Plans for the ReSeqTB Knowledgebase Tim Rodwell, Rebecca Colman, Anita Suresh & Claudia Denkinger IUTLD, Guadalajara, Mexico, 11 th October 2017 A TB
More informationLandscape and Language of Molecular Diagnostics for TB Drug Resistance
Landscape and Language of Molecular Diagnostics for TB Drug Resistance Purpose This module will provide: A brief overview of basic principles of molecular biology An introduction to mutations and their
More informationGENETIC DIVERSITY OF MDR TB: IMPLICATIONS FOR DIAGNOSTICS AND EVOLUTION
GENETIC DIVERSITY OF MDR TB: IMPLICATIONS FOR DIAGNOSTICS AND EVOLUTION Megan Murray, MD, MPH, ScD Harvard Medical School Brigham and Women s Hospital Harvard School of Public Heath INH Resistance All
More informationA cluster of MDR tuberculosis among asylum seekers in Switzerland and other European Countries
A cluster of MDR tuberculosis among asylum seekers in Switzerland and other European Countries Laboratory and Epidemiological Investigation Peter M. Keller, MD Deputy Head Swiss National Centre for Mycobacteria
More informationLabs, Ledgers, and Lives Saved: The Impact of Diagnostic Strategies on the Epidemiology and Economics of Tuberculosis
Labs, Ledgers, and Lives Saved: The Impact of Diagnostic Strategies on the Epidemiology and Economics of Tuberculosis David Dowdy, MD, PhD 9 th National Conference on Laboratory Aspects of Tuberculosis
More informationAssociation of gyra mutation in Mycobacterium tuberculosis isolates with phenotypic ofloxacin resistance detected by resazurin microtiter assay
Association of gyra mutation in Mycobacterium tuberculosis isolates with phenotypic ofloxacin resistance detected by resazurin microtiter assay Dr Asho Ali King Abdul Aziz University Jeddah, Saudi Arabia
More informationStool GeneXpert MTB/Rif Assay
Stool GeneXpert MTB/Rif Assay Standard Operating Procedure 1.0. Purpose The purpose of this standard operating procedure (SOP) is to detail the steps for correctly performing, interpreting, and documenting
More informationCurrent status of universal whole genome sequencing of Mycobacterium tuberculosis in the United States
Current status of universal whole genome sequencing of Mycobacterium tuberculosis in the United States Lauren Cowan, PhD Medical Consultant Meeting San Antonio, TX November 29-30, 2018 1 EXCELLENCE EXPERTISE
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Shah NS, Auld SC, Brust JCM, et al. Transmission of extensively
More informationDevelopment of drug resistance in M. tb and detection tests Cali, Colombia - March 28, 2007
Development of drug resistance in M. tb and detection tests Cali, Colombia - March 28, 2007 Hugo David 1970 20 Applied Microbiology 1970 20:810-814814 Probability distribution of drug-resistant resistant
More informationNoncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant.
Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant tuberculosis Policy statement March 2010 1 Contents Abbreviations Executive summary 1.
More informationData Sharing to Improve Management of Drug Resistant TB
Data Sharing to Improve Management of Drug Resistant TB Plans for Data Evaluation and Validation David L. Dolinger, Ph.D. 28 October 2014 Statement of the Challenge Challenge to develop a process by which
More informationDemocratizing Molecular Diagnostics: The GeneXpert MTB r test
Democratizing Molecular Diagnostics: The GeneXpert MTB r test David H. Persing, MD, PhD Executive Vice President Chief Medical and Technology Officer Cepheid Sunnyvale, CA Some Characteristics of an Ideal
More informationRecent Approaches in Detection of Drug- Resistant Tuberculosis. Dr M Hanif Bacteriologist Laboratory Division New Delhi Tuberculosis Centre
Recent Approaches in Detection of Drug- Resistant Tuberculosis Dr M Hanif Bacteriologist Laboratory Division New Delhi Tuberculosis Centre Newer Diagnostic Methods for MDR TB Rapid Culture and DST using
More information[[Page 63034]] ======================================================================= DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Federal Register Volume 79, Number 204 (Wednesday, October 22, 2014)] [Rules and Regulations] [Pages 63034-63036] From the Federal Register Online via the Government Printing Office [www.gpo.gov] [FR
More informationPositioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory. Giorgio Roscigno CEO FIND
Positioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory Giorgio Roscigno CEO FIND Integrated Laboratory Network Definition An integrated laboratory
More informationUse of whole genome sequencing of mycobacteria as a first line diagnostic clinical service in England. Tim Peto University of Oxford
Use of whole genome sequencing of mycobacteria as a first line diagnostic clinical service in England. Tim Peto University of Oxford Disclosures No financial conflicts of interest Funding NIHR Oxford Biomedical
More informationResearch Article Diagnostic Accuracy of Line Probe Assay for Detecting Multidrug Resistant Tuberculosis in Clinical Specimens
Cronicon OPEN ACCESS EC MICROBIOLOGY Research Article Diagnostic Accuracy of Line Probe Assay for Detecting Multidrug Resistant Tuberculosis in Clinical Specimens Bushra S 1 *, Shahid A 1, Aamer I 1, Luqman
More informationLaboratory Testing for Diagnosis and Treatment of TB
Laboratory Testing for Diagnosis and Treatment of TB Jennifer Rakeman, PhD Associate Director and Microbiology Manager Public Health Laboratory NYC Department of Health and Mental Hygiene Laboratory diagnosis
More informationBarriers on implementation of rapid methods of TB diagnosis
Barriers on implementation of rapid methods of TB diagnosis Turid Mannsåker National Reference Laboratory for Mycobacteria Norwegian Institute of Public Health TB in Norway around 1900: Among the highest
More informationWHO SRLs and Phenotypic Resistance
WHO SRLs and Phenotypic Resistance CPTR Rapid DST 2014 Workoshop Daniela M Cirillo, MD, PhD San Raffaele Scientific Institute Milan Outline SRLN EQAs Differences in data sets Delamanid testing: current
More informationCan whole genome sequencing replace AST?
Can whole genome sequencing replace AST? Matthew J Ellington Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright EUCAST Subcommittee on the role of whole
More informationThe role of PHE s AMRHAI Reference Unit
The role of PHE s AMRHAI Reference Unit Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright What does AMRHAI offer? Susceptibility
More informationNew Modalities in TB Diagnosis
New Modalities in TB Diagnosis The diagnosis in endemic countries depends more on the use of labour intensive, easy to use methodology with minimum infrastructure or equipment. The need is to find a viable
More informationConsiderations for Conventional Drug Susceptibility Testing and Molecular Detection of Drug Resistance
Considerations for Conventional Drug Susceptibility Testing and Molecular Detection of Drug Resistance Angela M Starks, PhD National TB Conference June 2013 National Center for HIV/AIDS, Viral Hepatitis,
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 Genotyping Lisa Armitige, MD, PhD May 08, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant financial
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Genotyping Basics for the Clinician Lisa Armitige, MD, PhD Wednesday April 6,2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationThe New Diagnostics WG and The Global Plan to Stop TB
The New Diagnostics WG and The Global Plan to Stop TB 2011-2015 Working Group on New Diagnostics Annual Meeting 11 th November 2010, Berlin Christian Lienhardt Stop TB Partnership Geneva Aims of this presentation
More informationExploding Head Zone The Interface of Molecular and Growth Based Drug Susceptibility Testing. Good News & Bad News:
Exploding Head Zone The Interface of Molecular and Growth Based Drug Susceptibility Testing Ed Desmond Diplomate, American Board of Medical Microbiology Good News & Bad News: Good: New technologies improve
More informationImplications of the genetic diversity within MTBC and M. canettii for the development of new DST assays
Implications of the genetic diversity within MTBC and M. canettii for the development of new DST assays Dr Claudio U. Köser, Peacock lab (Department of Medicine) Overview Importance of resistance mechanisms
More informationRapid diagnosis of drugresistant
Perspective Rapid diagnosis of drugresistant TB using line probe assays: from evidence to policy Expert Rev. Resp. Med. 2(5), 583 588 (2008) Daphne I Ling, Alice A Zwerling and Madhukar Pai Author for
More informationONSITE EVALUATION MECHANISM FOR CBNAAT LABORATORIES
ONSITE EVALUATION MECHANISM FOR CBNAAT LABORATORIES S Anand, Hema Sundaram, Reena K, Mamatha H G, Anupurba Roy Chowdhury BACKGROUND With the advent of molecular tests for the detection of tuberculosis,
More informationGrowing Needs for Practical Molecular Diagnostics: Indonesia s Preparedness for Current Trend
Growing Needs for Practical Molecular Diagnostics: Indonesia s Preparedness for Current Trend Dr. dr. Francisca Srioetami Tanoerahardjo, SpPK., MSi Essential Practical Molecular Diagnostics Seminar Hotel
More informationMonitoring and Evaluation Framework Specimen Referral Systems and Integrated Networks July 2018
and Evaluation Framework Specimen Referral Systems and Integrated Networks July 2018 1 Table of Contents Overview of monitoring and evaluating specimen referral systems... 3 Theory of change... 3 M&E framework...
More informationReference Standards for TB Microscopy Studies
Reference Standards for TB Microscopy Studies Andrew Whitelaw Andrew.Whitelaw@uct.ac.za Why Microscopy? Diagnose active TB Quick Cheap Still first choice in many resource limited settings Will detect NTMs
More informationPublic private partnerships
THE INTERNATIONAL CONFERENCE ON (RE-)EMERGING INFECTIOUS DISEASES 14 March 2018 in Addis Ababa, Ethiopia Public private partnerships Engaging the private research sector to scale up infectious diseases
More informationBANGLADESH. GxAlert for Real-time Management and Strengthening of Remote GeneXpert Network in Bangladesh PROJECT CONTEXT
TECHNICAL BRIEF Photo Credit: 2016 Md. Akram Ali, Courtesy of Photoshare GxAlert for Real-time Management and Strengthening of Remote GeneXpert Network in Bangladesh PROJECT CONTEXT The USAID-funded Challenge
More informationTB diagnostics: top 10 FAQs by test developers
13 November 2012 Kuala Lumpur TB diagnostics: top 10 FAQs by test developers Madhukar Pai, MD, PhD Associate Professor McGill University, Montreal madhukar.pai@mcgill.ca The TB dx landscape in 2012 is
More informationDiagnosing and Treating Drug Resistant TB in the 21st Century Using NGS and Intelligent Decision Support Tools
Diagnosing and Treating Drug Resistant TB in the 21st Century Using NGS and Intelligent Decision Support Tools Timothy C Rodwell MD, PhD, MPH 18 April 2017 APHL: 10 th National Conference on Laboratory
More informationThe TB diagnostic pipeline a realistic view
The TB diagnostic pipeline a realistic view Claudia Denkinger, MD PhD MSc Head of TB Programme at FIND 26 th October 2016, Union Meeting, Liverpool Understanding diagnostic needs: Diagnostics gaps in the
More informationResearch subgroup. Progress reports from the MDRTB WG Subgroups. Tbilisi, 21 September 2007
Research subgroup Progress reports from the MDRTB WG Subgroups Tbilisi, 21 September 2007 The history of the response to AIDS in Africa can be divided into two phases: 1. fiddling while Rome burns, and
More informationMOLECULAR LINE PROBE ASSAYS FOR RAPID SCREENING OF PATIENTS AT RISK OF MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB) POLICY STATEMENT
MOLECULAR LINE PROBE ASSAYS FOR RAPID SCREENING OF PATIENTS AT RISK OF MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB) POLICY STATEMENT 27 June 2008 POLICY STATEMENT MOLECULAR LINE PROBE ASSAYS FOR RAPID SCREENING
More informationPrediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
Original Article Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing The CRyPTIC Consortium and the 100,000 Genomes Project ABSTRACT BACKGROUND The World Health Organization
More informationPrediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
Original Article Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing The CRyPTIC Consortium and the 100,000 Genomes Project ABSTRACT BACKGROUND The World Health Organization
More informationCPTR 2013 Workshop September 30 th - October 3 rd. CPTR Roadmap: Accomplishments and Future Direction
CPTR 2013 Workshop September 30 th - October 3 rd CPTR Roadmap: Accomplishments and Future Direction CPTR Mission & Purpose Accelerate the development of new, safe, and highly effective regimens for TB
More informationUSING PYROSEQUENCING FOR DETECTION OF DRUG RESISTANCE
USING PYROSEQUENCING FOR DETECTION OF DRUG RESISTANCE Ed Desmond Acklnowledgment: Grace Lin, MS, Research Scientist Microbial Diseases Laboratory, CDPH 2012 MOLECULAR BEACON ASSAY (AT MDL) Target: DNA
More informationTechnical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products
Administrative Notice December 26, 2013 To: Division of Pharmaceutical Affairs, Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry
More informationMicrofluidics as an enabler for Medical Diagnostics
Microfluidics as an enabler for Medical Diagnostics Henne van Heeren, enablingmnt Microfluidics: The ability to create complex channel manifolds on a single substrate with no dead volume between connecting
More informationIncorporating New TB Diagnostics into RePORT
Incorporating New TB Diagnostics into RePORT Susan Dorman Johns Hopkins University School of Medicine REPORT MEETING, DURBAN, JULY 2016 MACS designed to: 1. Elucidate the natural history of the infection
More informationbased Tuberculosis Recording and Reporting System in China
Web-based based Tuberculosis Recording and Reporting System in China National Center for Tuberculosis Control and Prevention, China-CDC CDC 11 March 2011 Overview Infectious Disease Surveillance System
More informationTRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC
More informationBriefing: Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Karin Weyer 21 February 2011
Briefing: Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB Karin Weyer 21 February 2011 GeneXpert Xpert MTB/RIF 5 20 80 Samples per shift 500-1000 2 2 Multi-disease technology platform 3 >2010: CT/NG*;
More informationOraSure Technologies Jefferies 2016 Healthcare Conference
OraSure Technologies Jefferies 2016 Healthcare Conference Forward-Looking Statements These slides and the associated presentation contain certain forwardlooking statements, including statements with respect
More informationTechnical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis
Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis 2018 Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis
More informationForecast diagnostics for antimicrobial resistance (AMR)
Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford Context When asked to make forecasts
More informationTechnical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis
Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis 2018 Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis
More informationAdvances in the Diagnosis and Treatment of Tuberculosis San Antonio, Texas
Advances in the Diagnosis and Treatment of Tuberculosis San Antonio, Texas Molecular Detection of Drug Resistance Beverly Metchock, DrPH, D(ABMM) February 22, 2012 Beverly Metchock, DrPH, D(ABMM) has the
More informationMolecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018
Molecular Diagnostics at the Point of Need Interim Results (to Dec-17) 20 March 2018 2 Decentralising molecular diagnostics DOCUMENT INFORMATION The information contained in this document and made verbally
More informationA New Era of Clinical Diagnostics: How the Business Model is Changing.
A New Era of Clinical Diagnostics: How the Business Model is Changing. Nancy J Kelley, President and CEO of Nancy J Kelley & Associates Remarks to BTIG Emerging Technologies in Healthcare Diagnostics September
More informationResistance in TB: UK and Global perspectives; Laboratory detection
Resistance in TB: UK and Global perspectives; Laboratory detection BMST Meeting Friday 16 th May 2014 Ian Laurenson Scottish Mycobacteria Reference Laboratory Royal Infirmary of Edinburgh Ian.Laurenson@nhslothian.scot.nhs.uk
More informationMycobacterium tuberculosis End-Point PCR Kit Product# EP42100
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Mycobacterium tuberculosis End-Point PCR Kit Product# EP42100
More informationWhole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study
Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study Timothy M Walker*, Thomas A Kohl*, Shaheed V Omar*, Jessica Hedge*,
More informationUpdate on quality management using EQA and RemoteXpert
Update on quality management using EQA and RemoteXpert 1. Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Science, and NHLS, South Africa 2. Management Sciences
More informationEvaluation of Mycobacterium tuberculosis viability in OMNIgene-SPUTUM reagent upon multi-day transport at ambient temperature
Tagliani et al. BMC Infectious Diseases (2017) 17:663 DOI 10.1186/s12879-017-2756-3 TECHNICAL ADVANCE Open Access Evaluation of Mycobacterium tuberculosis viability in OMNIgene-SPUTUM reagent upon multi-day
More informationRole of Molecular Methods in Tuberculosis Diagnosis and Treatment
Role of Molecular Methods in Tuberculosis Diagnosis and Treatment Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory/Division of Tuberculosis Elimination June 2012 National Center for HIV/AIDS,
More informationSEQUENCING. M Ataei, PhD. Feb 2016
CLINICAL NEXT GENERATION SEQUENCING M Ataei, PhD Tehran Medical Genetics Laboratory Feb 2016 Overview 2 Background NGS in non-invasive prenatal diagnosis (NIPD) 3 Background Background 4 In the 1970s,
More informationHow can measurement science assist in improving AMR diagnostics research and development?
How can measurement science assist in improving AMR diagnostics research and development? Jim Huggett Principal Scientist, Nucleic Acid Research Molecular & Cell Biology, LGC Senior Lecturer, Analytical
More informationWGS for diagnosis of DR in TB: are we there yet? Union NAR, Vancouver 2/22/2017
WGS for diagnosis of DR in TB: are we there yet? Union NAR, Vancouver 2/22/2017 Maha Farhat MD MSc Department of Biomedical Informatics, HMS Pulmonary and Critical Care, MGH Two routes to drug resistance
More informationEuropean Tuberculosis Laboratory Initiative Regional TB and MDR-TB Diagnosis Workshop Report. Copenhagen, Denmark, August 2017
European Tuberculosis Laboratory Initiative Regional TB and MDR-TB Diagnosis Workshop Report Copenhagen, Denmark, 24 25 August 2017 ABSTRACT The European Tuberculosis Laboratory Initiative (ELI) regional
More informationEvolutionary Forces in Mycobacterium tuberculosis
Evolutionary Forces in Mycobacterium tuberculosis Sébastien Gagneux,, PhD 22 nd September, 2010 Molecular Typing of Mtb What is the question? (i.e. why are you genotyping your strains?) Use the Ideal Marker
More informationWISCONSIN STATE LABORATORY OF HYGIENE - UNIVERSITY OF WISCONSIN
Issues in Tuberculosis Drug Susceptibility Testing: TB Subcommittee White Papers Dave Warshauer, PhD D(ABMM) Deputy Director, CDD Wisconsin State Laboratory of Hygiene APHL TB Subcommittee John Bernardo
More informationUNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES
UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES Biodefense solutions to protect our nation Forward genomic surveillance advances DoD biomedical research toward combating high-consequence
More informationEvidence-based TB Diagnosis: how evidence informs practice and policy Madhukar Pai, MD, PhD
Evidence-based TB Diagnosis: how evidence informs practice and policy Madhukar Pai, MD, PhD Assistant Professor, McGill University, Montreal Co-Chair, Evidence Subgroup, New Diagnostics Working Group 1
More informationMICs in TB Susceptibility Testing: Challenges and Solutions for Implementation
MICs in TB Susceptibility Testing: Challenges and Solutions for Implementation Marie-Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories 8 th National Conference on Laboratory Aspects
More informationAbstract... i. Committee Membership... iii. Foreword... vii. 1 Scope Introduction Standard Precautions References...
Vol. 28 No. 12 Replaces MM18-P Vol. 27 No. 22 Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing; Approved Guideline Sequencing DNA targets of cultured isolates provides
More informationSeptember 8, General Comments:
September 8, 2009 AMP Comments on the draft report from the Agency for Healthcare Research and Quality (AHRQ): AHRQ Draft Report on Quality, Regulation and Clinical Utility of Laboratorydeveloped Tests.
More informationGDF Diagnostics. John Loeber Procurement Team Manager
GDF Diagnostics John Loeber Procurement Team Manager Joint UNICEF, UNFPA & WHO Meeting with Manufacturers and Suppliers Copenhagen, Denmark September 2013 1 GDF Diagnostics Overview 1. Standard Diagnostics
More informationExome Sequencing Exome sequencing is a technique that is used to examine all of the protein-coding regions of the genome.
Glossary of Terms Genetics is a term that refers to the study of genes and their role in inheritance the way certain traits are passed down from one generation to another. Genomics is the study of all
More informationOverview of CIDT Challenges and Opportunities
Overview of CIDT Challenges and Opportunities Peter Gerner-Smidt, MD, DSc Enteric Diseases Laboratory Branch InFORM II Phoenix, AZ, 19 November 2015 National Center for Emerging and Zoonotic Infectious
More informationUse of Molecular Assays for Resistance Detection
Use of Molecular Assays for Resistance Detection Antimicrobial resistance and susceptibility are complex, and current in vitro methods have been developed to predict a microorganism s response to antibacterial
More informationTBResist: A Global Consortium for Whole Genome Sequencing of Drug Resistant TB. IOM/IMCAS Meeting Beijing January 16-18, 2013
TBResist: A Global Consortium for Whole Genome Sequencing of Drug Resistant TB IOM/IMCAS Meeting Beijing January 16-18, 2013 Past and Future of TB Research I. Comas and S. Gagneux PLoS Pathog. 2009 October:
More information